EP Patent

EP1999136B1 — Peptidomimetic inhibitors of psma,compounds comprising them, and methods of use

Assigned to Cancer Targeted Technology LLC · Expires 2012-10-24 · 14y expired

What this patent protects

Patent listed against lutetium-lu-177-vipivotide-tetraxetan.

Drugs covered by this patent

Patent Metadata

Patent number
EP1999136B1
Jurisdiction
EP
Classification
—
Expires
2012-10-24
Drug substance claim
No
Drug product claim
No
Assignee
Cancer Targeted Technology LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.